-- The United Laboratories International (HKG:3933) unit Zhuhai United Bio-Pharmaceutical obtained approval for a clinical trial of dupilumab bio-similar from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
The approved indication is for atopic dermatitis.